Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs
| العنوان: | Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs |
|---|---|
| المؤلفون: | Szymon Mućka, Martyna Miodońska, Ewa Hadas, Andrzej Bozek, Magdalena Mroz, Dominika Ziolkowska |
| المصدر: | Medicina Volume 57 Issue 9 Medicina, Vol 57, Iss 881, p 881 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Medicine (General), medicine.medical_specialty, Exacerbation, Disease, Systemic therapy, Article, Virus, Psoriatic arthritis, R5-920, Psoriasis, Internal medicine, medicine, Humans, Pandemics, psoriatic arthritis, Biological Products, SARS-CoV-2, business.industry, COVID-19, General Medicine, medicine.disease, Real-time polymerase chain reaction, Observational study, business, biological drugs |
| الوصف: | Background and objectives: Biological treatment is an important and effective therapy for psoriasis. During the COVID-19 pandemic, it remains unclear whether this type of therapy affects the course of SARS-CoV-2 infection. The aim of the study was to observe patients with psoriasis undergoing biological or other systemic treatment in relation to the impact of SARS-CoV-2 infection on the course of psoriasis and the COVID-19 disease itself. Materials and methods: A one-year observational study included 57 patients with diagnosed psoriasis who qualified for biological treatment and a group of 68 similar patients who were administered a different systemic treatment. Patients were analyzed monthly for psoriasis (including Psoriasis Area Severity Index (PASI) assessment) and constantly for SARS-CoV-2 infection (telephone contact). Cases of COVID-19 were confirmed by Polymerase Chain Reaction (PCR) at the study center. Results: SARS-CoV-2 infection was confirmed by a positive Real Time Polymerase Chain Reaction (RT-PCR) test in eight patients (14.0%) with psoriasis on biological therapy. None of the cases in this group required hospitalization for COVID-19. Similar data were obtained in the control group. Specifically, 11 (16%) patients were confirmed to be infected with SARS-CoV-2. These results were statistically comparable (p > 0.05). In the group of patients undergoing biological treatment, six (75%) of eight patients developed an exacerbation of psoriasis during SARS-CoV-2 infection, and similar results were noted in the control group, with eight (72%) patients experiencing an exacerbation of psoriasis. Conclusions: Patients with psoriasis who were administered biological treatment or other systemic therapy may experience a mild course of SARS-CoV-2 infection but might also experience a temporary exacerbation of skin lesions. |
| وصف الملف: | application/pdf |
| تدمد: | 1648-9144 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2844b1da1fc92abd09db04e10d56f1feTest https://doi.org/10.3390/medicina57090881Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2844b1da1fc92abd09db04e10d56f1fe |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16489144 |
|---|